Evidence map›Paper›PMID 24649221›Full record

ArticleMolecular and clinical oncology2013

Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.

Kozo Kuribayashi, Shigeru Miyata, Kazuya Fukuoka, Aki Murakami, Syusai Yamada, Kunihiro Tamura, Noriko Hirayama, Takayuki Terada, Chiharu Tabata, Yoshihiro Fujimori and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. CPMKG: a condition-based knowledge graph for precision medicine.Database : the journal of biological databases and curation · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kozo KuribayashiDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Shigeru MiyataDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Kazuya FukuokaDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Aki MurakamiDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Syusai YamadaDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Kunihiro TamuraDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Noriko HirayamaDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Takayuki TeradaDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Chiharu TabataDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ;
Yoshihiro FujimoriCancer Center, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Takashi NakanoDivision of Respiratory Medicine, Department of Internal Medicine, Nishinomiya, Hyogo 663-8501, Japan ; ; Cancer Center, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Hyogo Prefectural Nishinomiya Hospital · JPHyogo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor of serosal surfaces with a poor prognosis. Methotrexate and gemcitabine have exhibited single-agent activity in MPM. We evaluated the feasibility of sequential administration of these agents in the treatment of MPM. A total of 21 patients with MPM received a 30-min infusion of 100 mg/m

Indexed as

chemotherapygemcitabinemalignant mesotheliomamethotrexate

Identifiers

PMID24649221
PMCPMC3916204
OpenAlexW2101988076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.